William Blair Forecasts Lower Earnings for Krystal Biotech

Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Analysts at William Blair decreased their Q2 2025 earnings per share estimates for Krystal Biotech in a report issued on Monday, July 14th. William Blair analyst S. Corwin now forecasts that the company will earn $1.12 per share for the quarter, down from their previous forecast of $1.36. The consensus estimate for Krystal Biotech's current full-year earnings is $6.14 per share. William Blair also issued estimates for Krystal Biotech's FY2026 earnings at $8.83 EPS.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a net margin of 37.17% and a return on equity of 14.64%. The company had revenue of $88.18 million during the quarter, compared to analyst estimates of $98.66 million.

Other equities analysts have also issued research reports about the company. Citigroup reissued a "neutral" rating and issued a $176.00 target price (up previously from $155.00) on shares of Krystal Biotech in a research note on Wednesday, July 9th. Chardan Capital reissued a "buy" rating and issued a $219.00 target price on shares of Krystal Biotech in a research note on Wednesday, May 7th. HC Wainwright reissued a "buy" rating and issued a $240.00 target price on shares of Krystal Biotech in a research note on Tuesday, June 24th. Finally, Guggenheim dropped their price target on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Krystal Biotech currently has an average rating of "Buy" and a consensus price target of $213.75.

Krystal Biotech Stock Performance

NASDAQ:KRYS traded down $0.57 during mid-day trading on Wednesday, hitting $149.58. The company had a trading volume of 41,522 shares, compared to its average volume of 286,351. Krystal Biotech has a fifty-two week low of $122.80 and a fifty-two week high of $219.34. The business's fifty day moving average is $136.27 and its two-hundred day moving average is $156.00. The firm has a market cap of $4.32 billion, a P/E ratio of 35.80 and a beta of 0.67.

Insider Activity at Krystal Biotech

In other news, insider Suma Krishnan sold 1,389 shares of the firm's stock in a transaction dated Wednesday, July 16th. The stock was sold at an average price of $150.00, for a total transaction of $208,350.00. Following the sale, the insider owned 1,508,056 shares of the company's stock, valued at $226,208,400. This trade represents a 0.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold a total of 49,800 shares of company stock worth $7,487,943 over the last quarter. Company insiders own 13.70% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Brooklyn Investment Group grew its holdings in shares of Krystal Biotech by 291.7% during the first quarter. Brooklyn Investment Group now owns 141 shares of the company's stock worth $25,000 after buying an additional 105 shares in the last quarter. Twin Tree Management LP bought a new position in shares of Krystal Biotech during the first quarter worth about $29,000. Fifth Third Bancorp grew its holdings in shares of Krystal Biotech by 159.1% during the first quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after buying an additional 105 shares in the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of Krystal Biotech by 128.3% during the first quarter. Smartleaf Asset Management LLC now owns 315 shares of the company's stock worth $58,000 after buying an additional 177 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of Krystal Biotech during the first quarter worth about $74,000. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).